SEC

166 contracts disclosed in SEC filings include authorizations to use U.S. patents without consent from patent holders

Posted on by KEI Staff

On 12 October 2022, Knowledge Ecology International (KEI) published a briefing note on the U.S. federal government FAR 52.227-1 authorizations (for non voluntary use of patents) disclosed in 166 SEC exhibits. KEI Briefing Note 2022:2, Federal government FAR 52.227-1 authorizations… Continue Reading →

Examples of SEC disclosures

The documents linked below provide examples of companies disclosing information related to drug R&D costs to the U.S. Securities and Exchange Commission (SEC). These documents are in the Google’s cloud-based Docs program. You can view and/or download them (no Google… Continue Reading →